Director Terrie Curran sold 8,687 shares of Arcutis Biotherapeutics Inc (ARQT, Financial) on November 11, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 10,139 shares of the company.
Arcutis Biotherapeutics Inc is a biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. The company's innovative approach targets various chronic and debilitating skin diseases.
Over the past year, Terrie Curran has engaged in multiple transactions involving the company's stock, selling a total of 8,687 shares and purchasing none. This recent sale is part of a broader trend observed within the company, where insider activity has predominantly consisted of sales. In the past year, there has been a total of 29 insider sales and only 1 insider buy at Arcutis Biotherapeutics Inc.
On the date of the latest transaction, shares of Arcutis Biotherapeutics Inc were priced at $10.85 each. The company's market cap stood at approximately $1.225 billion.
For further insights into the company's valuation metrics, such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors and analysts can visit the respective links.
This insider selling trend at Arcutis Biotherapeutics Inc provides a snapshot of the recent activities by company insiders, potentially offering insights into their perspective on the stock's future direction.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
